Safety shipping CAS 1156491-10-9 (1R,2S)-rel-2-(3,4-Difluorophenyl)cyclopropanamine hydrochloride Best Quality Lowest Price Best Quality Lowest Price

Ticagrelor is an oral antiplatelet drug, its American brand name is Brilinta, and its European brand name is Brilique. Ticagrelor is a reversible platelet adenosine diphosphate (ADP) receptor antagonist designed to prevent platelets from sticking together and forming blood clots that can lead to heart attacks and strokes. In the United States, ticagrelor was first approved by the FDA in July 2011 for the treatment of adult patients with acute coronary syndrome (ACS). Clinical data show that ticagrelor is significantly more effective than clopidogrel in reducing cardiovascular death for at least 12 months after an ACS event. In addition, ticagrelorChemicalbook also reduced the incidence of stent thrombosis (ST) in patients who had received stents to treat ACS. In June 2020, AstraZeneca announced that the U.S. Food and Drug Administration (FDA) had approved the anticoagulant Brilinta (ticagrelor) for use in patients with high-risk coronary artery disease (CAD) to reduce the risk of first heart attack. or risk of stroke. In November 2020, AstraZeneca announced that the U.S. Food and Drug Administration (FDA) had approved a new indication for the anticoagulant Brilinta (ticagrelor), in combination with aspirin, for the treatment of acute ischemia. In patients with hemorrhagic stroke or high-risk transient ischemic attack (TIA), it reduces the risk of subsequent stroke.